Help
Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
HOPKINTON, Mass., March 31 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today reported consolidated financial results for the year ended December 31, 2007 and company highlights.
"2007 was a year of significant clinical, regulatory, pipeline and business accomplishments that helped advance our mission of building a leading biopharmaceutical company focused on disorders of the central nervous system," commented Peter G. Savas, Chairman and Chief Executive Officer of Alseres. "Our progress reinforces our confidence in the broad potential of our pipeline and in our leadership in nerve repair and regenerative therapeutics. Our focus in 2008 will be on commencing the Phase IIb trial of CETHRIN, partnering our molecular imaging assets and closing collaborations for our regenerative therapeutics."
More: http://www.alseres.com/
Page 1 of 1
Cethrin - Clinical Trial In Acute Spinal Cord Injury Results
CETHRIN demonstrated an improvement
Rate Topic:
#1
- The Boss!
-
- Group: Moderators
- Posts: 3,427
- Joined: 03-November 03
- Gender:Male
- Country:UK
- Spinal Injury Level / Relationship:C5/6 Anterior Cord
Posted 01 April 2008 - 04:26 PM
Follow the Apparelyzed Forum on our Facebook and Twitter feeds.
#2
- Member
-
- Group: Members
- Posts: 422
- Joined: 23-October 07
- Gender:Female
- Country:Bergen County, NJ
- Spinal Injury Level / Relationship:T11 L2 Incomplete ASIA C
Posted 02 April 2008 - 03:35 PM
This is a very interesting and promising article. I went into their site and printed out news articles, program and product information. Looks like I have a lot of reading ahead of me.
Carole
Carole
"It's only the giving that makes you what you are." Tull
Share this topic:
Page 1 of 1